drugset
Drugs / megakaryocytic progenitor cells
last change Dec 2016 re-read 2 minutes ago

megakaryocytic progenitor cells

also known as MPs

Cell therapy

Developed for
thrombocytopenia
Investigated by
Academy Military Medical Science, China · Guangdong Provincial People's Hospital · Guangzhou First People's Hospital · Guangzhou General Hospital of Guangzhou Military Command · Huazhong University of Science and Technology · Nanfang Hospital, Southern Medical University
+5 more · Peking University People's Hospital · Southern Medical University, China · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sun Yat-sen University · Third Affiliated Hospital, Sun Yat-Sen University

Trials 1 · a red edge is where a trial was stopped

today NCT02241031 · Ph 2/3
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02241031 Sep 2014 → Sep 2016 thrombocytopenia Nanfang Hospital, Southern Medical University Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as megakaryocytic progenitor cells “ex vivo generated megakaryocytic progenitor cells (MPs)” NCT02241031 ↗
Known as MPs ClinicalTrials.gov intervention name — accepted as the source's own label NCT02241031 ↗
Modality Cell therapy “ex vivo generated megakaryocytic progenitor cells (MPs)” NCT02241031 ↗
Route Intravenous “MPs will be intravenously infused within 48 hours after chemotherapy.” NCT02241031 ↗